SARS-CoV-2重组S蛋白疫苗S-268019-b在食蟹猴中的免疫原性与保护效力
本研究在食蟹猴中评估了SARS-CoV-2重组S蛋白疫苗S-268019-b(抗原S-910823联合佐剂A-910823)的免疫原性与攻毒保护效力。不同剂量S-910823间隔3周肌内注射两次,第二剂后两周观察到剂量依赖性体液免疫应答,中和抗体滴度与人康复期血浆相当。10 µg S-910823免疫后对SARS-CoV-2攻毒显示保护效力,未观察到疫苗相关不良临床体征或体重下降,也未发现疫苗依赖性疾病增强。
要点
- S-268019-b由全长重组SARS-CoV-2 S蛋白S-910823与角鲨烯佐剂A-910823组成。
- 不同剂量S-910823间隔3周肌内注射两次,第二剂后两周观察到剂量依赖性体液免疫应答。
- 10 µg S-910823免疫后对SARS-CoV-2攻毒显示保护效力,未观察到疫苗相关不良临床体征或体重下降。
核心结论
- 当前发现为人体试验的疫苗剂量提供了基础信息,并支持将S-268019-b开发为安全有效的疫苗以控制当前大流行及对SARS-CoV-2的普遍保护。
研究设计与样本
- 研究在食蟹猴中评估S-268019-b的免疫原性,使用不同剂量的S-910823与A-910823联合,间隔3周肌内注射两次,第二剂后两周检测。
- 研究还评估了疫苗对SARS-CoV-2攻毒的保护效力。
主要发现
- 第二剂后两周观察到剂量依赖性体液免疫应答,中和抗体滴度与人康复期血浆相当。
- 携带Beta和Gamma变异株S蛋白的假病毒对两剂疫苗诱导的中和抗体的敏感性较祖先病毒约降低3至4倍,而对Omicron变异株中和抗体滴度降低超过14倍。
- 细胞免疫也被诱导,呈现相对Th1极化的应答。
- 未观察到与疫苗相关的临床不良体征或体重下降。
- 10 µg S-910823联合A-910823免疫后,根据鼻咽、咽和直肠拭子标本中的基因组和亚基因组病毒RNA转录本水平,显示对SARS-CoV-2攻毒的保护效力;病理分析未在攻毒后接种猴的肺中检测到疫苗依赖性疾病增强。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The vaccine S-268019-b is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-protein vaccine consisting of full-length recombinant SARS-CoV-2 S-protein (S-910823) as antigen, mixed with the squalene-based adjuvant A-910823. The current study evaluated the immunogenicity of S-268019-b using various doses of S-910823 and its vaccine efficacy against SARS-CoV-2 challenge in cynomolgus monkeys. The different doses of S-910823 combined with A-910823 were intramuscularly administered twice at a 3-week interval. Two weeks after the second dosing, dose-dependent humoral immune responses were observed with neutralizing antibody titers being comparable to that of human convalescent plasma. Pseudoviruses harboring S proteins from Beta and Gamma SARS-CoV-2 variants displayed approximately 3- to 4-fold reduced sensitivity to neutralizing antibodies induced after two vaccine doses compared with that against ancestral viruses, whereas neutralizing antibody titers were reduced >14-fold against the Omicron variant. Cellular immunity was also induced with a relative Th1 polarized response. No adverse clinical signs or weight loss associated with the vaccine were observed, suggesting safety of the vaccine in cynomolgus monkeys. Immunization with 10 µg of S-910823 with A-910823 demonstrated protective efficacy against SARS-CoV-2 challenge according to genomic and subgenomic viral RNA transcript levels in nasopharyngeal, throat, and rectal swab specimens. Pathological analysis revealed no detectable vaccine-dependent enhancement of disease in the lungs of challenged vaccinated monkeys. The current findings provide fundamental information regarding vaccine doses for human trials and support the development of S-268019-b as a safe and effective vaccine for controlling the current pandemic, as well as general protection against SARS-CoV-2 moving forward.
引用
- Hashimoto M, Nagata N, Homma T, et al. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. Vaccine. 2022. PMID: 35691872. doi:10.1016/j.vaccine.2022.05.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。